TERN Terns Pharmaceuticals, Inc.

NEUTRAL Impact: 4/10 EFFECT
Horizon weeks Filed May 8, 2026 Processed 1mo ago SEC 9999999995-26-001530
IPO/offering going effective
Latest settled — T+1d
TERN ▲ 0.00% at T+1d
NEUTRAL call ✗ call lost 0.00% · α vs SPY -0.23% · entry $52.95 → $52.95
Next anchor: T+5d due 26d ago
Entry anchored
May 8, 2026
via day open
T+1d
0.00%
call 0.00% · α -0.23%
$52.95
settled 4w ago
T+5d
call — · α —
due 26d ago
T+20d
call — · α —
due yesterday
T+60d
call — · α —
in 8w

Price Chart

Loading chart...

Executive Summary

Terns Pharmaceuticals' automatic shelf registration statement (S-3ASR) filed on December 9, 2025, became effective on May 7, 2026. This allows the company to offer and sell up to an undisclosed amount of common stock, preferred stock, debt securities, depositary shares, subscription rights, warrants, or units from time to time. The effectiveness creates a potential dilution overhang for existing shareholders, as the company can now conduct offerings at any time without further SEC review.

Actionable Insight

The shelf effectiveness gives Terns the flexibility to raise capital opportunistically. Monitor for prospectus supplements that would indicate an actual offering — any announced deal size above ~$100M could pressure the stock due to dilution. The cross-filing context shows this shelf was filed 150 days ago, so the effectiveness may simply be procedural, but the company's ability to tap the market at any time creates overhang.

Key Facts

  • Effectiveness date: May 7, 2026
  • Registration statement file number: 333-287092
  • Shelf registration covers common stock, preferred stock, debt securities, depositary shares, subscription rights, warrants, and units
  • Company qualifies as a well-known seasoned issuer (WKSI) under Rule 405
  • No specific offering size, pricing, or terms disclosed in the effectiveness notice
  • Prior S-3ASR filed on December 9, 2025, is the underlying registration

Financial Impact

Undisclosed — no offering size or pricing provided in the filing

dilutioncapital structure

Risk Factors

  • Potential dilution from future offerings under the shelf
  • No specific use of proceeds disclosed, creating uncertainty about capital allocation
  • Biotech sector sensitivity to equity issuance — any announced offering could weigh on share price

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
35% bullish (17 analysts)

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (Primary)9999999995-26-001530
Document: 9999999995-26-001530-index.html9999999995-26-001530
Document: 9999999995-26-001530.txt9999999995-26-001530
8 reports for TERN
Performance horizon
25% Hit rate 1 of 4 directional calls best @ T+1▲ +0.59%Mar 25, 2026
Filters
Rows
Reports for TERN — sortable, filterable
Type Now
May 15, 2026
25d ago
15-12G
BEARISH ★ 8/10
$52.97 awaiting T+1awaiting T+1
May 8, 2026
4w ago
EFFECT
NEUTRAL ★ 4/10
$52.95 $52.95· 0.00%▼ −0.23%
May 5, 2026
5w ago
8-K
NEUTRAL ★ 8/10
$52.95 $52.95· 0.00%▼ −1.38%
May 5, 2026
5w ago
25-NSE
BEARISH ★ 9/10
$52.95 $52.95· 0.00%▲ +1.38%
Apr 27, 2026
6w ago
8-K
BULLISH ★ 8/10
$52.95 $52.94▼ −0.02%▲ +0.47%
Apr 27, 2026
6w ago
Press Release
BULLISH ★ 8/10
$52.95 $52.94▼ −0.02%▲ +0.47%
Mar 25, 2026
10w ago
Press Release
BULLISH ★ 9/10
$52.86 $53.17▲ +0.59%▲ +2.36%
Feb 28, 2026
14w ago
Institutional Cluster
MIXED ★ 5/10
$42.03 $41.51▼ −1.24%▼ −0.32%
Showing 8 of 8

US Market Status

Market Closed — Opens in 9h

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access